Innovaderm Research Inc.
Diane Potvin is a seasoned statistician with extensive experience in biostatistics and pharmaceutical statistics. Currently serving as a Senior Statistical Advisor at Innovaderm Research Inc. since July 2022, Diane has also been the President of Excelsus Statistics since September 2012, specializing in consulting for various phases of clinical research. Previous roles include Biometrics Director at Theratechnologies, where Diane built and led a team that contributed to a successful FDA drug approval, and Director of Pharmaceutical Statistics at MDS Pharma Services, establishing a department focused on medical writing and statistics. Diane's earlier career includes positions at Institut Gustave Roussy, Université de Montréal, and Hôpital Saint-Sacrément, along with obtaining both a Master of Science and Bachelor of Science from Université Laval.
This person is not in any teams
This person is not in any offices
Innovaderm Research Inc.
1 followers
As a CRO (Clinical Research Organization) specialized in dermatology, we provide scientific guidance, accurate results and customer satisfaction. Our unique service offering combines specialized Contract Research Services, knowledge of dermatology sites in North America and Europe reach and the extended capabilities of a large clinical research site. The design and conduct of Phase 1 to Phase IV studies in Dermatology is our core expertise. Our specialized services include: • Study Design and Protocol Development • Submission to Regulatory Agencies and Central Ethics Committees • Regulatory Consulting • Trial Master Files Management • Project Management • Investigator / Site Selection • Patient Recruitment • Clinical Monitoring • Medical Monitoring • Pharmacovigilance • Data Management • Biostatistical Analysis • Clinical Study Report • Medical Writing / Publication Since 2000, Innovaderm has built a strong reputation for the quality of its research and the care offered to its study participants, its clients and its sites, often exceeding our client’s timeline expectations.